About HilleVax
HilleVax is a publicly listed company based in Boston (United States) founded in 2021 by David Socks. A norovirus vaccine is developed for infection prevention. HilleVax has raised $135 million across 1 funding round from investors including Lightspeed Venture Partners, Franklin Templeton and RA Capital. The company has 14 employees. HilleVax offers products and services including Norovirus Vaccine. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is HilleVax, Inc. Its competitors include Savara Pharma, VBI Vaccines and Icosavax; 3 of its 3 listed competitors have raised funding.
Company details
HilleVax was founded in 2021 and is based in Boston, United States. Focus is placed on biotechnology, specifically the development of vaccines against norovirus. The lead product, HIL-214, is a bivalent virus-like particle vaccine targeting GI.1 and GII.4 strains. Active immunization is provided to prevent acute gastroenteritis caused by norovirus, with operations centered on clinical advancement in the vaccine sector.
- Headquarters Boston, United States
- Employees 14
- Founders David Socks
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hillevax.com
- Social LinkedIn X
- Legal Name Hillevax, Inc.
- Net Profit-$147.27 M (USD)-19.18as on Dec 31, 2024
- EBITDA-$103.76 M (USD)20.91as on Dec 31, 2024
- Total Equity Funding$135M (USD)
in 1 rounds
- Latest Funding Round$135M (USD), Series D
Sep 2021
- InvestorsLightspeed Venture Partners
& 12 more
- Employee Count14
Products & Services of HilleVax
HilleVax offers a comprehensive portfolio of products and services, including Norovirus Vaccine.
Vaccine to prevent norovirus infections and reduce gastroenteritis outbreaks worldwide.
Funding Insights of HilleVax
HilleVax has successfully raised a total of $135M through 1 strategic funding round. The most recent funding activity was a Series D round of $135 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135M
- Total Rounds 1
- Last Round Series D — $135M
- First Round $135M
(Sep 2021)
- Investors Count 13
All 1 funding rounds of HilleVax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $135M | Series D | – | Frazier Healthcare Partners |
13 investors in total: 13 institutional.
Investors in HilleVax
HilleVax has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Franklin Templeton and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Investments in multiple sectors are made by Sahsen Ventures. | sahsen.com | Seattle, United States | ||
Healthcare companies are funded by Qiming, a venture capital firm. | qimingvcusa.com | Cambridge, United States | ||
Diversified investment management firm | 2000 | greenspringassociates.com | Owings Mills, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for HilleVax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HilleVax
23 people are tracked at HilleVax (12 in leadership, 2 in board & advisors, 9 in team); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
David Socks | Co-Founder | Leadership |
Anju Chatterji | Chief Technology Officer | Leadership |
Paul Bavier | General Counsel, Secretary & Chief Administrative Officer | Leadership |
Astrid Borkowski | Chief Medical Officer | Leadership |
Rob Hershberg | CEO, President & Chair | Leadership |
Aditya Kohli | COO | Leadership |
Lynn Ferrucci | Vice President Human Resources | Leadership |
Marlon Velasco | Vice President Information Technology | Leadership |
Heather Wheble | Senior Director, Legal | Leadership |
Shane Maltbie | Chief Financial Officer | Leadership |
Chao Huang | Senior Director | Leadership |
Amy E. | Director, Human Resources | Leadership |
Gary Dubin | Director | Board & advisors |
Nanette Cocero | Director | Board & advisors |
Ivana Dinkova, CPA, MBA | Corporate Controller | Team |
Elizabeth Bougoulas, CPA | Senior Manager, Financial Reporting | Team |
Sam Walker | Senior Scientist | Team |
Michael Abram | Scientific Consultant | Team |
Kristin Yannetti | Executive Assistant | Team |
Anthony Fiore | Senior Consultant | Team |
3 more people are available in the full profile.
Complete people profiles for HilleVax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HilleVax
HilleVax is a publicly listed company on the NASDAQ with ticker symbol HLVX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Apr 2022
- Listed onNASDAQ: HLVX
- Listed entityHilleVax, Inc.
- Exchange sectorHealth technology
- Share price$2.09 (-0.48% on the day) · 2025-09-18
- Market capitalisation$104.8M
- EPS (diluted, trailing year)$-1.43
- Volume (last session)2,800,167
- Analyst consensusNeutral
Financials of HilleVax
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$147.3M | -$103.8M | |
| 2023 | -$123.6M | -$131.2M | |
| 2022 | -$159.8M | -$60.4M | |
| 2021 | -$102.4M | -$15.8M |
Detailed financial statements for HilleVax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of HilleVax
3 dated milestones of HilleVax across 1 years, from founding to its latest funding, stage changes and deals.
- Founded HilleVax is founded.
- Funding First funding round of $135.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of HilleVax
HilleVax has 3 listed competitors in our database, 3 of them funded. They include Savara Pharma, VBI Vaccines and Icosavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| icosavax.com | 2017 | Seattle, United States | $152M | 60 | Developer of computationally designed VLP vaccines for treating multiple infections |
Detailed competitors of HilleVax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HilleVax
The website of HilleVax (hillevax.com) receives about 2K visits a month.
- Monthly visits2K
▼ 7.7% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as HilleVax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hillevax
Complete news archive for HilleVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HilleVax
HilleVax was founded in 2021.
HilleVax is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
HilleVax is a funded company, having raised a total of $135M across 1 funding round to date. The company's 1st funding round was a Series D of $135M, raised on Sep 2021.
HilleVax has 14 employees.
HilleVax was founded in 2021 and is based in Boston, United States. Focus is placed on biotechnology, specifically the development of vaccines against norovirus. The lead product, HIL-214, is a bivalent virus-like particle vaccine targeting GI.1 and GII.4 strains. Active immunization is provided to prevent acute gastroenteritis caused by norovirus, with operations centered on clinical advancement in the vaccine sector.
HilleVax's top competitors include Savara Pharma, VBI Vaccines and Icosavax.
HilleVax offers Norovirus Vaccine.
Yes, HilleVax is publicly traded on NASDAQ under the ticker symbol HLVX.
HilleVax has 13 investors. Key investors include Lightspeed Venture Partners, Franklin Templeton, RA Capital, Frazier Healthcare Partners, and Perceptive Advisors.
HilleVax operates through Hillevax, Inc..